Figure 7
Emergence of immature/transitional B cells after rhIL-7 administration. (A) Example of contour plot demonstrating the emergence of CD27−CD10+CD21low/high (immature/transitional) B cells at day 28. (B) Summary data from placebo and rhIL-7 recipients confirmed a statistically significant increase of the subset of immature/transitional B cells on day 28. PBMCs were gated on CD19+ cells and mature CD27+CD10+ B cells were excluded.

Emergence of immature/transitional B cells after rhIL-7 administration. (A) Example of contour plot demonstrating the emergence of CD27CD10+CD21low/high (immature/transitional) B cells at day 28. (B) Summary data from placebo and rhIL-7 recipients confirmed a statistically significant increase of the subset of immature/transitional B cells on day 28. PBMCs were gated on CD19+ cells and mature CD27+CD10+ B cells were excluded.

Close Modal

or Create an Account

Close Modal
Close Modal